Last $0.45 USD
Change Today 0.00 / 0.00%
Volume 0.0
UNISZ On Other Exchanges
Symbol
Exchange
NASDAQ GM
OTC US
Stuttgart
As of 8:10 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

unilife corp-cdi (UNISZ) Key Developments

Unilife Corporation Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Unilife Corporation reported audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported revenue of $14,689,000 against $2,743,000 a year ago. Operating loss was $51,395,000 against $61,058,000 a year ago. Interest income was $20,000 against $54,000 a year ago. Net loss was $57,899,000 against $63,198,000 a year ago. Basic and diluted loss per share was $0.59 against $0.78 per share a year ago. Net tangible assets per share negative were $0.06 against net tangible assets per share of $0.25 a year ago.

Unilife Corporation Reports Cash Flows Results for the Fourth Quarter and Full Year Ended June 30, 2014

Unilife Corporation reported cash flow results for the fourth quarter and full year ended June 30, 2014. For the fourth quarter, the company reported net cash flow used in operations of $20.009 million. Investment in physical non-current assets for the quarter was at $8.77 million. Receipts from customers were at $1.14 million. During the fourth quarter of fiscal year 2014, the company invested approximately $16 million in capital expenditures and R&D above normal quarterly investments. For the full year of 2014, the company reported net cash flow used in operations of $32.99 million. Investment in physical non-current assets for the full year was at $12.15 million. Receipts from customers were at $23.74 million.

Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers; Revises Earnings Outlook for the Full Year of 2014; Provides Outlook for the Full Year of 2015

Unilife Corporation announced an acceleration of investments in manufacturing capacity, R&D, and facilities in response to increasing demand from pharmaceutical and biotechnology companies for its products and services. During the fourth quarter of fiscal year 2014, the company invested approximately $16 million in capital expenditures and R&D above normal quarterly investments. The company has revised its full year revenue guidance for fiscal year 2014 to the high end of the $12 million to $15 million range that it announced previously. For the Full year 2015, the company anticipates revenue to show strong growth over fiscal year 2014. It expects to moderate itss investment in R&D during fiscal year 2015 while keeping SG&A largely flat. The increasing revenue and decrease in R&D investment is expected to allow the company to continue narrowing its operating income loss and operating cash flow loss during fiscal year 2015. As the mix of the revenue expands beyond fees and shifts toward commercial sales, the company expects to naturally increase its investment in capital expenditure.

Unilife Mulls Acquisitions

Unilife Corporation (ASX:UNS) filed a shelf registration. Unilife anticipate that the net proceeds from our sale of any securities will be used for general corporate purposes, including working capital, acquisitions, retirement of debt and other business opportunities.

Unilife Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014; Provides Revenue Guidance for the Fiscal Year 2014 and 2015

Unilife Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2014. For the quarter, the company reported revenue of $1.38 million compared to $0.69 million a year ago. Operating loss was $14.31 million compared to $13.50 million a year ago. Net loss was $15.11 million compared to $14.08 million a year ago. Net loss per basic and diluted common share was $0.15 compared to $0.17 a year ago. Adjusted net loss was $11.67 million compared to $9.40 million a year ago. Adjusted net loss per basic and diluted common share was $0.12 compared to $0.12 a year ago. This increase in adjusted net loss is primarily attributable to increased investment in R&D. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense. For the nine months, the company reported revenue of $8.14 million compared to $2.08 million a year ago. Operating loss was $37.02 million compared to $39.42 million a year ago. Net loss was $42.64 million compared to $41.22 million a year ago. Net loss per basic and diluted common share was $0.44 compared to $0.52 a year ago. Adjusted net loss was $27.05 million compared to $28.17 million a year ago. Adjusted net loss per basic and diluted common share was $0.28 compared to $0.36 a year ago. Net cash used in operating activities was $12.982 million against $30.91 million a year ago. Purchases of property, plant and equipment were $3.4 million against $1.931 million a year ago. The company provided revenue guidance for the fiscal year 2014 and 2015. The company expects fiscal year 2014 recognized revenue to be in the range of $12 million to $15 million. The company expects that revenue for financial year 2015 will be significantly higher than 2014 fiscal year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UNISZ:US $0.45 USD 0.00

UNISZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $117.17 USD +0.69
Insulet Corp $36.11 USD +0.11
Terumo Corp ¥2,618 JPY +5.00
West Pharmaceutical Services Inc $43.43 USD -0.02
Ypsomed Holding AG SFr.85.00 CHF 0.00
View Industry Companies
 

Industry Analysis

UNISZ

Industry Average

Valuation UNISZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 29.3x
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UNILIFE CORP-CDI, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.